Literature DB >> 25107348

Characterization of mitochondrial bioenergetic functions between two forms of Leishmania donovani - a comparative analysis.

Subhasish Mondal1, Jay Jyoti Roy, Tanmoy Bera.   

Abstract

Leishmaniasis is a growing health problem in many parts of the world partly due to drug resistance of the parasite. This study reports on the fisibility of studying mitochondrial properties of two forms of wild-type L. donovani through the use of selective inhibitors. Amastigote forms of L. donovani exhibited a wide range of sensitivities to these inhibitors. Mitochondrial complex II inhibitor thenoyltrifluoroacetone and FoF1-ATP synthase inhibitors oligomycin and dicyclohexylcarbodiimide were refractory to growth inhibition of amastigote forms, whereas they strongly inhibited the growth of promastigote forms. This result indicated that complex II and FoF1-ATP synthase were not functional in amastigote forms suggesting the presence of attenuated oxidative phosphorylation in the mitochondria of amastigote forms. In contrast, mitochondrial complex I inhibitor rotenone and complex III inhibitor antimycin A inhibited cellular multiplication and substrate level phosphorylation in amastigote forms, suggesting the role of complex I and complex III for the survival of amastigote forms. Further we studied the mitochondrial activities of both forms by measuring oxygen consumption and ATP production. In amastigote form, substantial ATP formation by substrate level phosphorylation was observed in NADPH-fumarate, NADH-fumarate, NADPH-pyruvate and NADH-pyruvate redox couples. None of the redox couple generated ATP formation was inhibited by FoF1-ATP synthase inhibitor oligomycin. Therefore, we may conclude that there are significant differences between these two forms of L. donovani in respect of mitochondrial bioenergetics. Our results demonstrated bioenergetic disfunction of amastigote mitochondria. Therefore, these alterations of metabolic functions might be a potential chemotherapeutic target.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25107348     DOI: 10.1007/s10863-014-9569-5

Source DB:  PubMed          Journal:  J Bioenerg Biomembr        ISSN: 0145-479X            Impact factor:   2.945


  27 in total

1.  On respiratory impairment in cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-08-10       Impact factor: 47.728

2.  Identification of the terminal respiratory chain in kinetoplast . mitochondrial complexes of Leishmania tropica promastigotes.

Authors:  E Martin; A J Mukkada
Journal:  J Biol Chem       Date:  1979-12-10       Impact factor: 5.157

3.  Quantitative ultrastructural investigations of mitochondrial development in Leishmania donovani during transformation.

Authors:  R Brun; S M Krassner
Journal:  J Protozool       Date:  1976-11

4.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

5.  The bioenergetic signature of cancer: a marker of tumor progression.

Authors:  José M Cuezva; Maryla Krajewska; Miguel López de Heredia; Stanislaw Krajewski; Gema Santamaría; Hoguen Kim; Juan M Zapata; Hiroyuki Marusawa; Margarita Chamorro; John C Reed
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

6.  The experimental chemotherapy of leishmaniasis. II. The activity in tissue culture of some antiparasitic and antimicrobial compounds in clinical use.

Authors:  N M Mattock; W Peters
Journal:  Ann Trop Med Parasitol       Date:  1975-09

7.  Mitochondrial complex I is deficient in renal oncocytomas.

Authors:  Helene Simonnet; Jocelyne Demont; Kathy Pfeiffer; Leila Guenaneche; Raymonde Bouvier; Ulrich Brandt; Hermann Schagger; Catherine Godinot
Journal:  Carcinogenesis       Date:  2003-07-04       Impact factor: 4.944

8.  The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis.

Authors:  José M Cuezva; Guoan Chen; Andrés M Alonso; Antonio Isidoro; David E Misek; Samir M Hanash; David G Beer
Journal:  Carcinogenesis       Date:  2004-02-12       Impact factor: 4.944

9.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

10.  Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection.

Authors:  Jayati Mookerjee Basu; Ananda Mookerjee; Rajdeep Banerjee; Manik Saha; Subhankar Singh; Ksudiram Naskar; Gayetri Tripathy; Prabhat K Sinha; Krishna Pandey; Shyam Sundar; Sanjeev Bimal; Pradip K Das; Soumitra K Choudhuri; Syamal Roy
Journal:  Antimicrob Agents Chemother       Date:  2007-12-03       Impact factor: 5.191

View more
  3 in total

1.  Synthesis and evaluation of the antileishmanial activity of silver compounds containing imidazolidine-2-thione.

Authors:  Patrícia Ferreira Espuri; Larissa Luiza Dos Reis; Eduardo de Figueiredo Peloso; Vanessa Silva Gontijo; Fábio Antônio Colombo; Juliana Barbosa Nunes; Carine Ervolino de Oliveira; Eduardo T De Almeida; Débora E S Silva; Jessica Bortoletto; Daniel Fonseca Segura; Adelino V G Netto; Marcos José Marques
Journal:  J Biol Inorg Chem       Date:  2019-04-04       Impact factor: 3.358

2.  Unraveling of interacting protein network of chaperonin TCP1 gamma subunit of Leishmania donovani.

Authors:  Shailendra Yadav; Apeksha Anand; Karthik Ramalingam; Deep Chandra Balodi; Jaswinder Singh Maras; Neena Goyal
Journal:  Cell Stress Chaperones       Date:  2022-02-23       Impact factor: 3.827

3.  Macromolecular biosynthetic parameters and metabolic profile in different life stages of Leishmania braziliensis: Amastigotes as a functionally less active stage.

Authors:  Marlene Jara; Maya Berg; Guy Caljon; Geraldine de Muylder; Bart Cuypers; Denis Castillo; Ilse Maes; María Del Carmen Orozco; Manu Vanaerschot; Jean-Claude Dujardin; Jorge Arevalo
Journal:  PLoS One       Date:  2017-07-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.